How FDA Expanded Access for Daraxonrasib and Phase 3 Survival Data At Revolution Medicines (RVMD) Has Changed Its Investment Story
Revolution Medicines recently secured FDA clearance for an expanded access program for its investigational pancreatic cancer drug daraxonrasib,…